Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Peter Verdult
EB
Peter Verdult
Exane BNP Paribas
Wall Street Analyst
★★☆☆☆
#1911
on 13Foresight · ranked by our own returns
38%
Success Rate
+1.2%
Average Return
5 of 13 calls profitable · -14.6% vs benchmark
📈 Across the calls we could measure, roughly 38% of Peter Verdult's ratings turned a profit when each position was held for 1 year — averaging +1.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

1 Buy 3 Hold 0 Sell
Peter's Stock Coverage 35 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
SNY
Sanofi
 Apr 20, 2026 HOLD Strong Buy
+74.4% avg upside
20 analysts
$50.00
18.05% Upside
 -2.7%
RHHBY
Roche Holding
 Mar 17, 2026 HOLD Buy
+0.3% avg upside
14 analysts
$50.00
0.62% Upside
 +0.9%
NVO
Novo Nordisk
 Aug 13, 2025 HOLD Buy
+168.8% avg upside
26 analysts
$54.00
24.98% Upside
 -10.4%
GB:0NZT
UCB SA
 Jun 27, 2025 BUY Buy
-15.2% avg upside
19 analysts
$182.00
27.09% Downside
 ·
CH:ROP
Roche Holding AG
 Apr 16, 2025 BUY Buy
+3.3% avg upside
23 analysts
$300.00
6.24% Downside
 ·
DE:MRK
Merck KGaA
 Apr 16, 2025 SELL Buy
+2.2% avg upside
32 analysts
$107.00
19.54% Downside
 ·
FR:IPN
Ipsen
 Apr 16, 2025 HOLD Buy
-21.9% avg upside
17 analysts
$100.00
36.07% Downside
 ·
GB:AZN
AstraZeneca
 Apr 16, 2025 BUY Strong Buy
+12.2% avg upside
26 analysts
$11500.00
13.10% Downside
 ·
GB:GSK
GlaxoSmithKline
 Apr 16, 2025 HOLD Hold
-2.9% avg upside
25 analysts
$1350.00
29.89% Downside
 ·
CH:GALD
Galderma Group AG
 Apr 16, 2025 BUY Strong Buy
+5.1% avg upside
10 analysts
$100.00
42.06% Downside
 ·
FR:SAN
Sanofi
 Apr 16, 2025 BUY Strong Buy
+32.9% avg upside
30 analysts
$115.00
55.05% Upside
 ·
CH:NOVN
Novartis AG
 Apr 16, 2025 BUY Buy
-9.8% avg upside
30 analysts
$95.00
19.77% Downside
 ·
NVS
Novartis
 Apr 15, 2025 BUY Hold
-7.5% avg upside
24 analysts
$116.00
21.21% Downside
 +42.5%
GSK
GlaxoSmithKline
 Apr 15, 2025 HOLD Hold
-13.9% avg upside
19 analysts
$35.25
30.41% Downside
 +68.5%
BMY
Bristol-Myers Squibb
 Oct 25, 2024 HOLD Buy
+9.1% avg upside
42 analysts
$55.00
1.91% Upside
 -11.4%
LLY
Eli Lilly & Co
 Oct 25, 2024 BUY Strong Buy
-10.5% avg upside
47 analysts
$1250.00
13.76% Upside
 -6.8%
MRK
Merck & Company
 Oct 25, 2024 BUY Strong Buy
+10.7% avg upside
43 analysts
$130.00
14.15% Upside
 -13.4%
RPRX
Royalty Pharma
 Oct 25, 2024 BUY Strong Buy
+4.2% avg upside
15 analysts
$40.00
24.42% Downside
 +42.1%
DE:BAYN
Bayer
 Oct 17, 2024 HOLD Strong Buy
+33.6% avg upside
28 analysts
$29.00
23.37% Downside
 ·
GB:0DPB
Bavarian Nordic AS
 Oct 01, 2024 BUY Strong Buy
+99.6% avg upside
5 analysts
$294.00
67.54% Upside
 ·
GB:0QIU
Novo Nordisk
 Sep 27, 2024 BUY Hold
+43.2% avg upside
28 analysts
$975.00
232.42% Upside
 ·
GB:HIK
Hikma Pharmaceuticals
 Aug 09, 2024 BUY Buy
+64.1% avg upside
7 analysts
$2845.00
95.20% Upside
 ·
CH:IDIA
Idorsia Ltd
 Jun 21, 2024 SELL Hold
-26.7% avg upside
8 analysts
$1.30
77.07% Downside
 ·
GB:0MGB
Genmab A/S
 Jun 04, 2024 SELL Buy
+31.5% avg upside
22 analysts
$1860.00
13.35% Upside
 ·
NL:LKFT
Galapagos
 Apr 17, 2024 HOLD Sell
+112.9% avg upside
16 analysts
$30.00
21.94% Upside
 ·
GRFS
Grifols SA
 Mar 01, 2024 BUY Buy
+247.6% avg upside
12 analysts
$26.40
256.73% Upside
 +19.6%
ES:GRF
Grifols
 Jan 10, 2024 BUY Buy
+64.4% avg upside
12 analysts
$23.00
152.71% Upside
 ·
GB:SBRY
J Sainsbury plc
 Sep 27, 2023 HOLD Hold
+992.1% avg upside
8 analysts
$295.00
1.65% Downside
 ·
EVO
Evotec AG
 Jun 08, 2023 BUY Strong Buy
+288.1% avg upside
9 analysts
 — -61.7%
DE:EVT
Evotec
 Jun 08, 2023 BUY Buy
+258.9% avg upside
8 analysts
$31.60
582.54% Upside
 ·
GMAB
Genmab
 Dec 20, 2022 HOLD Buy
+38.3% avg upside
26 analysts
 — -29.2%
LKFT
Lakefront Biotherapeutics
 Jan 27, 2022 BUY Hold
+272.6% avg upside
24 analysts
 — ·
CH:LONN
Lonza Group Ltd
 Jul 28, 2021 HOLD Strong Buy
+26.0% avg upside
19 analysts
$680.00
36.44% Upside
 ·
BAYRY
Bayer
 Mar 20, 2019 BUY Buy
+293.9% avg upside
9 analysts
 — -22.8%
HKMPY
Hikma Pharmaceuticals
 Mar 19, 2019 BUY Strong Buy
1 analyst
 — ·
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Peter Verdult — Frequently Asked Questions
How accurate are Peter Verdult's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Peter's ratings were profitable over a one-year hold, with an average return of +1.2% per rating, or -15.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Peter ranked on 13Foresight?
Peter Verdult is currently ranked #1911 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Peter cover?
Peter most recently has ratings on SNY, RHHBY, NVO, GB:0NZT, CH:ROP, DE:MRK, FR:IPN, GB:AZN, GB:GSK, CH:GALD, FR:SAN, CH:NOVN and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.